Findings

What do systematic reviews say?

1,060 questions · 1,105 findings · 84 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 434 · 39.3%GRADE not reported 32 · 2.9%Very low 246 · 22.3%Low 237 · 21.4%Moderate 132 · 11.9%High 24 · 2.2%

Metformin vs glucagon like peptide‐1 analogues

Cardiovascular mortality

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

Non‐fatal MI

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

Non‐fatal stroke

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

End‐stage renal disease

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

Serious adverse events

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 112 participants
GRADE not reported

Metformin vs meglitinides

Health‐related quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

Cardiovascular mortality

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs insulin

Cardiovascular mortality

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

Non‐fatal MI

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

Non‐fatal stroke

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

End‐stage renal disease

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs insulin

Non‐fatal MI

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs insulin

Non‐fatal stroke

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs insulin

End‐stage renal disease

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs sulphonylureas

All‐cause mortality

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 3129 participants
Very low

Metformin vs sulphonylureas

SAEs

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 3081 participants
Very low

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

All‐cause mortality · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Metformin · people at increased risk for developing type 2 diabetes

2 findings from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 201 participants
Low
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Acarbose · people at increased risk for developing type 2 diabetes

2 findings from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
Very low
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found